Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
59.08B
Market cap59.08B
Price-Earnings ratio
14.28
Price-Earnings ratio14.28
Dividend yield
0.16%
Dividend yield0.16%
Average volume
1.58M
Average volume1.58M
High today
$554.00
High today$554.00
Low today
$520.50
Low today$520.50
Open price
$547.88
Open price$547.88
Volume
2.71M
Volume2.71M
52 Week high
$1,211.20
52 Week high$1,211.20
52 Week low
$520.50
52 Week low$520.50

REGN News

TipRanks 4d
Regeneron’s Promising Pipeline: Itepekimab’s Potential Impact on COPD Market and Stock Rating

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $958.00. Te...

Analyst ratings

73%

of 26 ratings
Buy
73.1%
Hold
19.2%
Sell
7.7%

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.